Zidebactam
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Zidebactam
- Molecular weight
- 391.41
- Structure (SMILES)
- O=C(NNC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O)[C@@H]1CCCNC1
- ertapenam zidebactam
- Ertapenam-Zidebactam
- wck 5107
- WCK 5107
- wck 5107 1000
- WCK 5107 1000
- wck 5107 250 mg to 2000 mg
- WCK 5107 250 mg to 2000 mg
- WCK-5107
- wck5107
- WCK5107
- zidebactam
- Zidebactam
- zidebactam [INN]
- ZIDEBACTAM [USAN]
- Zidebactam [WHO-DD]
- zidebactam inn
- zidebactam usan
- zidebactam who dd
- Zidebactam, (-)-
- CAS registry numbers
- 1436861-97-0
- ChEMBL ID
- CHEMBL4533605
- InChIKey
- YCZPXRQPDCXTIO-BBBLOLIVSA-N
- PubChem compound IDs
- 77846445
- RxNorm IDs (RxCUI)
- 2744813
- FDA ingredient codes (UNII)
- YPM97423DB
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- zidebactam
- Type
- Synthetic organic
- Drug name stem
- -bactam
- Approval recorded by Guide to Pharmacology
- Yes
Investigated indications
- Condition
- Bacterial Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition identifier
- EFO_0000771
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003529
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100338
- Highest recorded phase
- 3
Trial references
- NCT05645757
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 4
- Polar surface area
- 157.38
- Calculated partition coefficient (ALogP)
- -1.86
- Calculated partition coefficient (XLogP)
- -4.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 26
- Molecular formula
- C13H21N5O7S
- Monoisotopic mass
- 391.11616920
- Natural product
- Yes
- Recorded assays
- 291
- Active assays
- 6
Active assay types
- Confirmatory
Related records
Trials (6)
- A Single-center, Open-label, Study Evaluating Safety and Pharmacokinetics of Single Doses of Zidebactam-Cefepime and Metronidazole Alone or in Combination.
- MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults
- Safety Study of Intravenous Ertapenem in Combination With Zidebactam (WCK 6777)
- Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
- Study of the Metabolism and Excretion of Zidebactam (WCK 5107) Following a Single Intravenous Infusion.
- This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
In development for (3)
- Acute pyelonephritis Phase 3
- Bacterial infectious disease Phase 1
- Urinary tract infection Phase 3